• Journal of Evidence-Based Herbal Medicine
• /
• v.1 no.2
• /
• pp.17-26
• /
• 2008

Nowadays the flow of international trade is that there seems to appear economic block significantly because most countries contract FTAs, so our market condition is changing to a severe competitive situation. Korea which has 70% of foreign dependence of trade must get involved in regionalism, and also actively promote FTA more than any other countries. FTA on February in 2006, the pharmaceutical industry are anxious. The pharmaceutical industry in Korea has recently come to a crisis that it is hard to expect a growth due to structure of profit and a change for the worse of management. If Korea-U.S. FTA are contracted in this kind of situation, domestic pharmaceutical companies will be at stake. We can anticipate that FTA with the country that has a strong competitive power like U.S. affect negatively on pharmaceutical industry, because the industry doesn't have enough self-competitiveness. Considering this kind of surroundings, we need to present the policy to enhance competitiveness for damage limitation on pharmaceutical industry by Korea-U.S. FTA. Under this background, this research has groped for a direction to strengthen the competitiveness to develop pharmaceutical industry in quality. The competitive enhancement plan is presented which is divided into the government policy part, the R&D part, and the management part. Although Korea-U.S. FTA is analyzed to wither the pharmaceutical industry, it would be thought that it is a good chance to upgrade domestic pharmaceutical industry if we make the best use of it, and also to make in roads into foreign market.

• Korean Journal of Clinical Pharmacy
• /
• v.31 no.3
• /
• pp.171-179
• /
• 2021

Background: Need for regulatory science is emerging with the development of pharmaceutical industry. It is essential to train regulatory science experts to meet the needs of technology and regulations to evaluate advanced products. Major regulatory science countries are conducting the regulatory science activities and fostering the experts. Methods: Published literature and the relevant website of European Union (EU) were reviewed and criteria were developed. In particular, we focused on in depth descriptions of the Innovative Medicines Initiative program, which was conducted twice. Results: EU is striving to provide funding and training experts for the development of the regulatory science by horizon 2020 and regulatory science to 2025. Innovative medicines initiative (IMI) is a public-private partnership aimed at the development of the pharmaceutical industry, including the regulatory science. IMI education and training projects have provided various education and training course including short-term curriculum and master and doctoral course. The difference between South Korea's regulatory science expert training project in 2021 and the EU's IMI education and training projects is participation of pharmaceutical companies. While the pharmaceutical companies participate in the IMI project to select project topics and form a community, South Korea's project is focused on the Ministry of Food and Drug Safety and universities. Conclusion: Through successful active networks with regulatory party, pharmaceutical companies, and universities, a great innovative advance of regulatory science in South Korea is expected.

• Journal of Korean Society of Industrial and Systems Engineering
• /
• v.44 no.3
• /
• pp.192-206
• /
• 2021

The pharmaceutical industry is an industry that provides medicines related to the health and life of the people. The pharmaceutical industry is a traditional regulation industry with the characteristics of R&D(Research and Development), purchasing, manufacturing, distribution and consumption under strict government management. Until now, pharmaceutical companies have continued to make efforts to maintain competitiveness through patent management, new product development, and marketing. However, industries are rapidly changing, including rising costs for developing new products and expanding generic markets. As these changes and uncertainties in the management environment increase, efforts are required to improve the competitiveness of the pharmaceutical industry from a new perspective. In this study, we intend to examine the impact of SCM(Supply Chain Management) dynamic capability of pharmaceutical companies on corporate performance through partnerships to respond to market changes and uncertainties. It was determined that the agility, visibility and flexibility that constitutes the SCM dynamic capabilities would affect the performance of pharmaceutical companies. In this study, the importance of SCM dynamic capabilities and cooperative relationships was identified through surveys by SCM managers of pharmaceutical companies. Consequently, in the pharmaceutical industry, which is a regulatory industry, we have identified that SCM dynamic capabilities and cooperative relationships with partner companies have a significant impact on corporate performance.

• Journal of Korean Society of Industrial and Systems Engineering
• /
• v.17 no.31
• /
• pp.125-139
• /
• 1994

The purpose of this paper is to study the problems to be solved in the marketing strategy aspect by domestic pharmaceutical industry under the competitive market circumstances with multinational pharmaceutic enterprises. The major concern has been paid to the key ideas and practical methods to be needed in strengthening the competitive marketing power of domestic pharmaceutical industry against multinational pharmaceutical enterprises. In this article, the researcher is to analyze the current situations and problems of domestic pharmaceutical industry and finally the researcher is to provide the major ideas concerning the problems to be solved in the marketing strategy aspect by domestic pharmaceutical industries.

• Korean Journal of Clinical Pharmacy
• /
• v.31 no.4
• /
• pp.257-267
• /
• 2021

Background: The need for regulatory science development to evaluate advanced regulatory products is gradually increasing without hindering the technological development. Creating a research environment and fostering experts through the establishment of regulatory agency-led policies are essential for the development of regulatory science. Method: This is a comparative study of the United States, Japan, Singapore, and Korea. The literature and websites of each regulatory agency were reviewed, and the focus was on advantages and comparing advantages based on definition, development trends, and expert training projects. Results: The United States is striving to develop regulatory science in response to changes in the new pharmaceutical industry through the regulatory science report, and to foster expert both inside and outside the Food and Drug Administration (FDA). Japan is promoting regulatory science centered on regulatory science centers, and is focusing on researching work-related regulatory science within the Pharmaceuticals and Medical Devices Agency (PMDA) and improving employees' ability to make regulatory decisions. Singapore was aiming to improve Southeast Asia's regulatory capabilities under the leadership of Centre of Regulatory Excellence (CoRE) within Duke-NUS University. In 2021, Korea is in its early stages, starting to run a university's degree program related to regulatory science this year. Conclusion: Regulatory science should be developed with the aim of improving the regulatory ability of the Ministry of Food and Drug Safety with Korea's independent concept of regulatory science.

• YAKHAK HOEJI
• /
• v.58 no.6
• /
• pp.397-404
• /
• 2014

The Ministry of Health and Welfare proposed the "undergraduate program specializing in pharmaceutical industry" in 2013, as part of its roadmap to assist domestic pharmaceutical companies to become the top-tier pharma companies in near future and provide skilled personnel tailored for pharmaceutical industry. However, it is not clear whether this "undergraduate program" meets the needs of pharmaceutical industry, especially when the number of pharmacy students increased from 1,200 to 1,700 per year since 2009. The purpose of this paper is to identify which educational background is preferred by pharmaceutical companies, by surveying the CEOs of domestic pharmaceutical companies and referring to recruitment advertisements shown in medical newspapers, specified by the fields within the companies. Two independent reviewers referred to recruitment session in Yakup newspaper and Dailypharm from May 2012 until January 2014, focusing on recruitments from pharmaceutical companies targeting bachelors' degree holders with no prior experience. 749 recruitments were observed during the study period, more than 90% of which were provided by domestic pharmaceutical companies, and regardless of the companies being domestic or multinational, pharmaceutical companies' preference for pharmacists was remarkable (44.3% for domestic and 65.8% for multinational), and the preference was especially high in the fields such as Medical, R&D, Market Access (regulatory affair/pricing and reimbursement), Business Development, and Marketing. Survey results showed that the need of establishing the undergraduate program specializing in pharmaceutical industry is mixed, suggesting that although there is need for the educating personnel targeting pharmaceutical industry, the undergraduate program would not be an answer due to current PEET system. Our study concludes that in the example of pharmaceutical companies' recruitments shown in medical newspapers, pharmaceutical companies prefer pharmacy major in almost all fields of the pharmaceutical companies, yet the pharmaceutical companies still perceive the gap between current bachelor's degree holders(including pharmacy majors) and the ideal personnel required for advancing to the "top-class" pharmaceutical companies.

• Korean Journal of Clinical Pharmacy
• /
• v.33 no.1
• /
• pp.43-50
• /
• 2023

Background and Objective: With the advancement of cancer treatments and increased life expectancy, managing breakthrough cancer pain (BTcP) is essential to improve the quality of life for cancer patients. This study aimed to compare the major rapid onset opioids in Korea based on their characteristics and costs to determine the best option for each patient. Methods: Based on sales information from IQVIA-MIDAS, sublingual fentanyl tablet (SLF), fentanyl buccal tablet (FBT), and oral transmucosal fentanyl citrate (OTFC) were selected as the top three drugs for the treatment of BTcP in Korea, considering them the most comparable drugs. The cost and cost-pain relief ratio of the drugs for short-term (1 month) and long-term (1 year) treatment were compared and the ease of administration based on various factors, including pharmacokinetics, onset of action, and administration procedures were evaluated. Results: SLF was evaluated as the best overall in terms of rapid onset of action, ease of administration, and drug cost and also had the highest market share. SLF had the lowest cost pain relief ratio for both the initial and supplemental treatment for the 1-month pain intensity difference 15 (PID15) ratio. However, for the 1-month PID30 ratio, SLF was not superior to OTFC or FBT. The longer the breakthrough cancer pain duration, the more cost-effective the other rapid onset opioids. Conclusion: The rapid onset opioids that fit the patient's breakthrough cancer pain pattern have the best cost-effectiveness.

• YAKHAK HOEJI
• /
• v.56 no.2
• /
• pp.116-125
• /
• 2012

Local pharmaceutical companies in Korea, which have grown focusing on domestic markets, have recently faced difficulties such as market saturation, price control policies and market-opening pressures by FTA. It seems to be an urgent issue for them to export pharmaceuticals to developed countries comprising the greater part of the global pharmaceutical market. Hence, this research was conducted to investigate and benchmark the strategies employed by India industry for the successful access to the global pharmaceutical markets. Drug policies as well as their influences on pharmaceutical market changes between India and Korea for the last 40 years have been searched and the differences have been comparatively analyzed. The pharmaceutical industry of India has the following strengths: low costs; experienced labor pool; excellent reverse-engineering skills; powerful IT; marketing capability; and established distribution network. After 2000, consolidations, M&A and alliances with domestic and multinational companies have been sharply increased in the industry of India. Indian companies unfolding both competition and cooperation with multinational corporations currently move up the value-added chain, and this enthusiastic strategy should be learned by local pharmaceutical companies.

• Journal of Distribution Science
• /
• v.19 no.8
• /
• pp.13-24
• /
• 2021

Purpose: This research is aimed to explore factors affecting on Kazakhstan's pharmaceutical distribution industry, selection of various factors and assessment of the level of their influence. Based on the literature review it was defined that there is a great variety of scientific works relating to pharmaceutical distribution industry competitiveness and management improvement. Research design, data and methodology: There is very little research, which to determine the issues of pharmaceutical industry distribution in developing countries, in particular EAEU countries. The algorithm was chosen for research provision: statistical and comparative analysis, correlation, and regression analysis. The data of 1993-2020 obtained from the World Bank, Bureau of National Statistics, National Bank of Kazakhstan, which is expressed by 19 factors as macroeconomic indicators. Results: The chosen variables were selected non-randomly, these economic indicators had the most reliable, unique, and utmost for the whole research period complete information. Conclusions: There could be made adequate conclusions of the research, there is a strong positive relationship for six factors: population, GDP per capita, average annual US dollar exchange rate, the minimum pension, average assigned monthly pension, minimum wage. Pension and wage are the most significant factors affecting on the pharmaceutical distribution industry in Kazakhstan.

• Knowledge Management Research
• /
• v.19 no.3
• /
• pp.189-223
• /
• 2018

This paper examined the effect of innovation networks comprising research and development (R&D) collaboration on innovation performance of Korean pharmaceutical firms. As co-assigned patents and co-affiliated publications are common technical outcomes of successful R&D collaboration in the pharmaceutical industry, social network analysis technique was applied for analyzing innovation networks through patent and publication data. Results of Social network analysis indicated that a small set of highly innovative firms in the Korean pharmaceutical industry were actively involved in patenting and publishing. And the analysis of structural equation model found the followings: (1) R&D intensity significantly affected patenting, publication and new drug development, (2) the activity of patenting and publishing was positively related with the innovation performance measured by new drug development, and (3) R&D collaboration in terms of degree centrality of co-patent network played significant moderating roles on the relationships among R&D intensity, patenting, and new drug development. These findings are expected to be helpful to researchers as well as policy-makers to devise innovation-promoting policies in the Korean pharmaceutical industry. Discussions and limitations of the study are provided in the last part.